Reprometabolic Syndrome Mediates Subfertility in Obesity (NCT02653092)
🩺 Plain-English Summary (8th-Grade Level)
Obesity plays an adverse role at every stage of conception and pregnancy and mounting evidence implicates relative hypogonadotropic hypogonadism, and reduced menstrual cycle hormone secretion as likely contributors to the subfertility phenotype and possible contributors to complications of pregnancy and the developmental origin of adult diseases such as diabetes and cardiovascular disease. This study will be the first comprehensive investigation to tie together the patterns of hyperinsulinemia, hyperlipidemia and inflammation, characteristic of obesity and obesity-caused relative hypogonadotropic hypogonadotropism and its potential adverse reproductive outcomes. The investigators findings will be used to inform a subsequent clinical intervention to optimize reproductive outcomes for obese women and their offspring.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Denver — Aurora, Colorado
Age range: 18 Years to 38 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Colorado Denver — Aurora, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) — Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.